Peringkat dalam Saham
#35026
Tricida, Inc. operates as a biopharmaceutical firm with a primary focus on the... Tricida, Inc. operates as a biopharmaceutical firm with a primary focus on the advancement and market introduction of veverimer (TRC101). This compound, an orally ingested, non-systemic polymer, has successfully concluded its Phase III clinical trials. Veverimer is designed to address metabolic acidosis in individuals suffering from chronic kidney disease by specifically targeting and eliminating excess acid within the gastrointestinal tract. The company was established in 2013 and is headquartered in South San Francisco, California.
Harga Saham
$0.108
Terakhir disinkronkan: 2023-01-23
Kapitalisasi Pasar
$4.56M
Perubahan (1 hari)
-10.00%
Perubahan (1 tahun)
0.00%
Perdagangan Tricida, Inc. (TCDA)
Harga TCDA dengan kapitalisasi pasar B
Kapitalisasi pasar dari Tricida, Inc.(TCDA)
Kapitalisasi Pasar: $4.56M
Per August 2026, Tricida, Inc. memiliki kapitalisasi pasar sebesar $4.56M. Ini menjadikan Tricida, Inc. sebagai perusahaan 35026th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Tricida, Inc. dari 2018 hingga 2026
TCDA dibandingkan dengan 5 teratas stocks paling populer
| Harga TCDA |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.452T
|
+119,424,252.46%
|
|
|
|
|
$4.490T
|
+98,354,771.67%
|
|
|
|
|
$4.162T
|
+91,178,334.11%
|
|
|
|
|
$3.676T
|
+80,530,983.42%
|
|
|
|
|
$2.833T
|
+62,058,316.97%
|
